2008
DOI: 10.1016/j.ab.2007.09.007
|View full text |Cite
|
Sign up to set email alerts
|

A DNA aptamer with high affinity and specificity for therapeutic anthracyclines

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
2
1
1
1

Citation Types

2
68
0

Year Published

2008
2008
2022
2022

Publication Types

Select...
7
2

Relationship

0
9

Authors

Journals

citations
Cited by 101 publications
(70 citation statements)
references
References 45 publications
2
68
0
Order By: Relevance
“…The control results agree with surface plasmon resonance findings in which nonspecific binding of daunomycin to control sequence DNA aptamers was not observed. 38 It should also be noted that the increase in SHG signal is not due to incoherent hyper-Rayleigh scattering of daunomycin nor daunomycin aggregates in the bulk solution. This is shown in Figure 2 where the SHG signal did not change, within experimental error, as the daunomycin concentration increased in the absence of DNA coated microparticles.…”
Section: ■ Results and Discussionmentioning
confidence: 96%
“…The control results agree with surface plasmon resonance findings in which nonspecific binding of daunomycin to control sequence DNA aptamers was not observed. 38 It should also be noted that the increase in SHG signal is not due to incoherent hyper-Rayleigh scattering of daunomycin nor daunomycin aggregates in the bulk solution. This is shown in Figure 2 where the SHG signal did not change, within experimental error, as the daunomycin concentration increased in the absence of DNA coated microparticles.…”
Section: ■ Results and Discussionmentioning
confidence: 96%
“…To demonstrate this ability, we first emplaced E-AB sensors for the detection of the cancer chemotherapeutic doxorubicin (DOX) (29,30) in the external jugular vein of anesthetized Sprague-Dawley rats (Fig. 1C).…”
Section: Resultsmentioning
confidence: 99%
“…Encouraged by these successful test case design efforts, we next adapted our simple strategy to engineering cooperativity into two structurally more complex receptors. For the first, we employed a sequence based on the doxorubicin-binding aptamer of Wochner et al (36), which binds this important cancer chemotherapeutic with a dissociation constant of ∼200 nM. Of note, the 3D structure of this aptamer is not known, rendering this a significantly more challenging test of our design approach.…”
Section: Resultsmentioning
confidence: 99%